Cargando…
Letter to the Editor Regarding: Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia, Proskorovsky et al. Adv Ther (2019);36(8):2147–2160. doi:10.1007/s12325-019-00991-w
Autores principales: | Song, Jinlin, Gao, Wei, Xie, Jipan, Tiwana, Simran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6999160/ https://www.ncbi.nlm.nih.gov/pubmed/31838710 http://dx.doi.org/10.1007/s12325-019-01168-1 |
Ejemplares similares
-
Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia
por: Song, Jinlin, et al.
Publicado: (2019) -
Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia
por: Proskorovsky, Irina, et al.
Publicado: (2019) -
Inotuzumab ozogamicin and blinatumomab sequential therapy for relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
por: Ueda, Tomoaki, et al.
Publicado: (2022) -
Primary refractory B-cell lymphoblastic leukemia with extramedullary disease – a distinctive response to blinatumomab and inotuzumab ozogamicin
por: Silva, Wellington Fernandes da, et al.
Publicado: (2019) -
Inotuzumab ozogamicin for acute lymphoblastic leukaemia
Publicado: (2019)